ALFASIGMA SPA
- Country
- 🇮🇹Italy
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.alfasigma.com
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.
- Conditions
- Diverticulitis
- Interventions
- Other: Placebo
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 193
- Registration Number
- NCT03469050
- Locations
- 🇮🇹
AOU Cagliari - Policlinico Monserrato Gastroenterologia, Cagliari, Italy
🇩🇪Medamed GmbH Studienambulanz Leipzig, Leipzig, Germany
🇫🇷Centre Hospitalier Regional Universitaire Claude Huriez Service de Chirurgie Digestive et Générale, Lille, France
Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas
- Conditions
- Inoperable Solid Tumors or Lymphomas
- Interventions
- Drug: AvidinOX
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 3
- Registration Number
- NCT03188328
- Locations
- 🇺🇸
Dep. of Investigational Cancer Therapeutics - U. T. M. D. Anderson Cancer Center, Houston, Texas, United States
A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 430
- Registration Number
- NCT03106922
- Locations
- 🇫🇷
Hôpital Jeanne de Flandre, Lille, France
🇫🇷University and Pediatric Hospital of Lyon, Lyon, France
🇮🇹Ospedale Maggiore "C.A. Pizzardi" AUSL Bologna, Bologna, Italy
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 2731
- Registration Number
- NCT03025308
- Locations
- 🇺🇸
Rheumatology Associates of North Alabama, PC, Huntsville, Alabama, United States
🇺🇸Arthrocare, Arthritis Care & Research PC, Gilbert, Arizona, United States
🇺🇸Arizona Arthritis & Rheumatology Associates, P.C., Tucson, Arizona, United States
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
- Conditions
- BACTERIAL VAGINOSIS
- Interventions
- Drug: PLACEBO VAGINAL TABLET
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 392
- Registration Number
- NCT02376972
- Locations
- 🇺🇸
College of Medicine Drexel University, Philadelphia, Pennsylvania, United States
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
- Conditions
- Malaria, Vivax
- Interventions
- Drug: Eurartesim tablets
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 27
- Registration Number
- NCT02110784
- Locations
- 🇳🇱
Dep. Infectious Disease, Section Travel Medicine, Leiden University Medical Centre, Leiden, Netherlands
🇨ðŸ‡Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
🇩🇪Medizinische Klinik mit Schwerpunkt Infektiologie, Charite/Campus Virchow-Klinikum, Berlin, Germany
AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Liver Metastases
- Interventions
- Combination Product: AvidinOX/ST2210
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 14
- Registration Number
- NCT02053324
- Locations
- 🇮🇹
Ospedale dell' Angelo di Mestre, Mestre, Venice, Italy
🇦🇹Allgemeines Krankenhaus Wien, Wien, Austria
🇮🇹Ospedale S. Maria Goretti, Latina, Rome, Italy
Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Drug: Rifaximin-EIR
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2010-02-22
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 410
- Registration Number
- NCT00528073
- Locations
- 🇮🇱
Bnai Zion Medical Center, Haifa, Israel
🇫🇷CHU Amiens, Hôpital Nord, Amiens Cedex, France
🇫🇷CHU Grenoble, Hôpital Michallon, Grenoble Cedex 9, France